

# In vivo enhancer analysis of human conserved non-coding sequences

Len A. Pennacchio<sup>1,2</sup>, Nadav Ahituv<sup>2</sup>, Alan M. Moses<sup>2</sup>, Shyam Prabhakar<sup>2</sup>, Marcelo A. Nobrega<sup>2,†</sup>, Malak Shoukry<sup>2</sup>, Simon Minovitsky<sup>2</sup>, Inna Dubchak<sup>1,2</sup>, Amy Holt<sup>2</sup>, Keith D. Lewis<sup>2</sup>, Ingrid Plajzer-Frick<sup>2</sup>, Jennifer Akiyama<sup>2</sup>, Sarah De Val<sup>4</sup>, Veena Afzal<sup>2</sup>, Brian L. Black<sup>4</sup>, Olivier Couronne<sup>1,2</sup>, Michael B. Eisen<sup>2,3</sup>, Axel Visel<sup>2</sup> & Edward M. Rubin<sup>1,2</sup>


Identifying the sequences that direct the spatial and temporal expression of genes and defining their function *in vivo* remains a significant challenge in the annotation of vertebrate genomes. One major obstacle is the lack of experimentally validated training sets. In this study, we made use of extreme evolutionary sequence conservation as a filter to identify putative gene regulatory elements, and characterized the *in vivo* enhancer activity of a large group of non-coding elements in the human genome that are conserved in human–pufferfish, *Takifugu (Fugu) rubripes*, or ultra-conserved<sup>1</sup> in human–mouse–rat. We tested 167 of these extremely conserved sequences in a transgenic mouse enhancer assay. Here we report that 45% of these sequences functioned reproducibly as tissue-specific enhancers of gene expression at embryonic day 11.5. While directing expression in a broad range of anatomical structures in the embryo, the majority of the 75 enhancers directed expression to various regions of the developing nervous system. We identified sequence signatures enriched in a subset of these elements that targeted forebrain expression, and used these features to rank all 3,100 non-coding elements in the human genome that are conserved between human and *Fugu*. The testing of the top predictions in transgenic mice resulted in a threefold enrichment for sequences with forebrain enhancer activity. These data dramatically expand the catalogue of human gene enhancers that have been characterized *in vivo*, and illustrate the utility of such training sets for a variety of biological applications, including decoding the regulatory vocabulary of the human genome.

Significant progress has been made in the identification of core promoter elements based on their defined position immediately upstream of each gene and their nearly universal activation by RNA polymerase II<sup>2,3</sup>. However, the identification of distant acting gene regulatory sequences that direct precise spatial and temporal patterns of expression has been limited, despite their established roles in development<sup>4</sup>, phenotypic diversity<sup>5</sup> and human disease<sup>6–8</sup>. Comparative genomic-based approaches have proved to be useful in identifying gene regulatory sequences, primarily on a gene-by-gene basis. These studies involved sequence comparisons of human (or other vertebrate) genomic intervals to orthologous regions from organisms separated by varying evolutionary distances, ranging from primates to fish<sup>9–12</sup>. From this work it has been implied that ancient conservation (such as between human and fish) as well as ‘ultra’-conservation among mammals (sequences at least 200 base pairs (bp) in length that are 100% identical among human/mouse/rat)<sup>1</sup> may be useful indicators of sequences with an increased likelihood of demonstrating gene regulatory activity. These gene-centric investigations,

however, have identified only a relatively small number of distant-acting enhancer sequences.

As one of the goals of this work was to assess the validity of a genome-based approach, rather than a gene-centric one, we chose non-coding target sequences based on one of two ‘extreme’ comparative genomic criteria: ancient conservation between human and *Fugu* (separated by ~450 million years of evolution) or ultra-conservation among human/mouse/rat<sup>1</sup>. In total, 167 human DNA fragments were assessed for spatial enhancer activity in a well-established transgenic mouse enhancer assay that links the human conserved fragment to a minimal mouse heat shock promoter fused to a *lacZ* reporter gene<sup>10,13–16</sup>. We chose to determine tissue-specific reporter gene expression at embryonic day 11.5 (e11.5), as this developmental stage allows for whole-mount staining and whole-embryo visualization. Moreover, at this time-point many of the major tissues and organs have been specified. We also expected this stage to be particularly informative because ‘extreme’ conserved non-coding elements tend to be enriched and clustered near genes expressed during embryonic development<sup>1,12,17,18</sup>.

Overall, we found that 29% (24/83) of human–*Fugu* elements alone and 61% (33/54) of human–*Fugu* elements that are also ultraconserved were positive enhancers in this *in vivo* assay




**Figure 1 | A summary of all sequences tested for enhancer activity in transgenic mice.** **a**, A breakdown of the assayed non-coding sequences by human–*Fugu* conservation and/or human–rodent ultraconservation: Human–*Fugu* only, human–*Fugu* and human–rodent, or human–rodent only. **b**, The total percentage of positive human enhancers broken down by the same parameters as described in **a**. The total number of elements tested is indicated within **a**, while the number of positives is found above the bars of the graph in **b**.

<sup>1</sup>US Department of Energy Joint Genome Institute, Walnut Creek, California 94598, USA. <sup>2</sup>Genomics Division, MS 84-171, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA. <sup>3</sup>Molecular and Cellular Biology Department, University of California-Berkeley, California 954720, USA. <sup>4</sup>Cardiovascular Research Institute, University of California, San Francisco, California 94143-2240, USA. †Present address: Department of Human Genetics, University of Chicago, Chicago, Illinois 60637, USA.

(Fig. 1; Supplementary Table 1; the entire data set including the sequence coordinates, conservation, and whole-mount embryo digital imagery can be accessed and queried at the VISTA Enhancer Browser, <http://enhancer.lbl.gov>). As an example of these data, we present 23 elements meeting our selection criteria that were located in a gene-poor 2.5 Mb stretch bracketing *SALL1*, a gene encoding a transcription factor expressed in early development and mutated in Townes-Brooks syndrome<sup>19</sup> (Fig. 2). Seven of the elements flanking *SALL1* directed tissue-specific reporter gene expression in the transgenic *in vivo* assay, recapitulating aspects of *SALL1*'s endogenous expression characteristics at e11.5<sup>20</sup> and further supporting the postulated modular nature of distant acting gene enhancers<sup>21,22</sup>. In addition, we tested 30 ultraconserved non-coding sequences that lacked identifiable conservation with *Fugu* of which 18 (60%) functioned as enhancers, similar to the success rate observed for ultraconserved elements that also have *Fugu* conservation (Fig. 1). Whereas the average size of the human fragments tested was 1,270 bp, the positive enhancers overlapped longer human–rodent conserved regions (average length 1,630 bp versus 966 bp; *t*-test *P*-value=0.0087; see Supplementary Methods) and were more conserved among mammals (human–rodent conservation score, *t*-test *P*-value=0.0004; see Supplementary Methods) relative to negatives in the assay.

These experimental results reveal the high propensity of extremely conserved human non-coding sequences to behave as transcriptional enhancers *in vivo*, and support both ancient human–fish conservation and human–rodent ultraconservation as highly effective filters to identify such functional elements. The large percentage of elements positive for enhancer activity is particularly surprising, considering the single time-point of investigation and the likely possibility that a fraction of the negatives may be enhancers active either earlier or later in development. An important question arising from the significant fraction of ultra and *Fugu* conserved elements functioning as enhancers is whether the tissue-specific enhancer activity that we assess completely explains why these sequences are so constrained. Overlaying our data set with results from a recent ChIP-Chip study<sup>23</sup> indicates that at least seven of the elements reported here (including four that are enhancers at e11.5) presumably function as gene silencers in embryonic stem cells. Such data imply that functions in addition to tissue-specific transcriptional activation are embedded in some fraction of extremely conserved



**Figure 2 | A 3 Mb region of human chromosome 16 enriched for human–*Fugu* non-coding conservation flanking the *SALL1* gene.** The coordinates and gene annotations located at the top of the diagram are based on the hg17 assembly at the UCSC Genome Browser (<http://genome.ucsc.edu>). The middle tracks depict human fragments that were tested in the transgenic mouse enhancer assay, and their classification as either ‘negative’ or ‘positive’ refers to their enhancer activity at e11.5. All human elements tested were conserved in the *Fugu* genome, and two of these elements were also defined as ultraconserved (denoted by arrowheads). The bottom panel indicates the positive enhancer activities captured through transgenic mouse testing of human–*Fugu* conserved non-coding fragments in this interval.


500

non-coding elements, thus potentially contributing to their extreme level of constraint. However, the high efficiency of enhancer identification through this approach nonetheless suggests that tissue-specific transcriptional enhancer activity may be one of the predominant functions of non-coding genomic regions under extreme constraint throughout vertebrate evolution.

We categorized all 75 identified enhancers by their general anatomical patterns of expression using an existing standardized nomenclature<sup>24</sup> (Fig. 3). All positive enhancer annotations are based on a minimum of three independent transgenic *F<sub>0</sub>* embryos carrying the same construct and demonstrating the same expression pattern, though the majority (83%) had four or more supporting embryos. We observed reporter gene expression in a variety of anatomical regions, including embryonic structures that are subject to major morphogenetic and remodelling events at e11.5, such as the developing limb, the somites, the heart and the branchial arches (Fig. 3). Of the 16 distinct anatomical structures where expression was noted, it was most frequently observed in the central and peripheral nervous system, with the most prevalent patterns corresponding to forebrain, midbrain, neural tube, and hindbrain (Fig. 3). This bias may be partially explained by the intrinsic complexity of the genetic cascades underlying vertebrate nervous system development<sup>25</sup> as well as the high percentage of all genes that are expressed in the nervous system.

The majority of the enhancers (50 elements, 66%) directed reproducible expression only to a single anatomical structure at the resolution of whole-mounts. This is consistent with the notion that complex endogenous messenger RNA expression patterns commonly result from the combined effects of several independent *cis*-regulatory sequences. The remaining one-third (25/75) of the enhancers directed expression to two or more anatomical structures. We speculate that these enhancer elements may be composed of two or more adjacent functional modules that are too tightly linked to each other to be resolved by our comparative approach, or that several tissue-specific enhancer activities overlap within a single enhancer element that is used in more than one developmental process. Importantly, the enhancer data set reported here provides a sizeable sequence-based substrate to begin to dissect these possible regulatory mechanisms, as well as reagents for further in-depth biological investigation.

To explore if our *in vivo* enhancer data set could be used to identify sequence features associated with elements driving reporter gene expression in specific anatomical structures, we focused on the forebrain as a test case and selected as a training set four of the strongest



**Figure 3 | Grouping of positive expression patterns captured in the transgenic mouse enhancer assay.** The total number of elements displaying a given anatomical pattern is depicted by the height of the bars in the chart. A representative transgenic embryo is provided for each expression pattern. Elements with reproducible staining in more than one structure are included in each respective category.

enhancers identified early on in our survey. Using a motif finding strategy, we identified six motifs significantly over-represented in these enhancers (see Supplementary Methods). We then scored and ranked all ~3,100 human–*Fugu* conserved non-coding elements in the human genome (Supplementary Table 2) for the statistical over-representation of these putative forebrain motifs (Supplementary Methods). The 30 highest-ranking elements included the four known forebrain enhancers that constituted the training set as well as 26 additional elements (Supplementary Table 3). Of these 26 elements, 23 were successfully cloned and tested for *in vivo* enhancer activity in transgenic mice. We observed robust forebrain enhancer activity for 4 of the 23 elements (17%) tested in the transgenic assay system. By comparison, only 4 (5%) of the 77 otherwise uncharacterized human–*Fugu* conserved elements used to identify the training set were forebrain enhancers (see Supplementary Methods; Fig. 4). This preliminary result, although based on a small training set, indicates that a combined comparative and motif-based strategy provided a greater than threefold enrichment ( $P = 0.08$ , see Supplementary Methods) over comparative-only approaches for the identification of enhancers active in a particular tissue of interest. This initial computational investigation also highlights the need for larger characterized enhancer training sets, the annotation of tissue specificities at high spatial resolution and the development of improved computational methods, which will probably provide a substrate to conclusively establish the predictive power of such approaches.

This study provides quantitative support for previous anecdotal observations that ‘extreme’ evolutionary non-coding conservation is a powerful predictor of mammalian tissue-specific enhancers. Of note, there are at least an additional 5,500 human–fish conserved non-coding sequences in the human genome with similar levels of

constraint that are strong candidates for acting as gene enhancers<sup>11</sup>. The efficiency of enhancer identification coupled with the relatively high throughput transgenic assay used here represents a feasible approach for the generation of a genome-wide experimentally validated enhancer data set. Such collections are expected to define functional candidate regions as medical sequencing efforts escalate, as well as provide a foundation for inferring the network of regulatory interactions among key developmental genes during vertebrate development, analogous to the well-developed efforts in non-vertebrate model systems<sup>21,22</sup>. Regulatory insights derived from these analyses should also enable the creation of modules driving pre-determined expression patterns for various biological applications, as well as contribute to an understanding of the vocabulary and grammar of DNA sequences dictating gene expression.

## METHODS

**Identification of conserved elements and transgenic enhancer assay.** Human–*Fugu* conserved non-coding elements with 70% identity, a score of match-mismatch  $\geq 60$ , and lacking evidence of encoding a protein or being transcribed in mRNA were derived from whole-genome alignments (see Supplementary Methods). The coordinates of ultraconserved elements were retrieved from ref. 1. Conserved elements were amplified from human genomic DNA by polymerase chain reaction (PCR), sequence-validated and transferred into an *Hsp68-LacZ* reporter vector. Generation of transgenic mice and embryo staining was done as previously described<sup>26</sup> in accordance with protocols approved by the Lawrence Berkeley National Laboratory. For each enhancer fragment, all transgenic embryos exhibiting LacZ-staining were scored and annotated independently by multiple curators.

**Motif identification and prediction of forebrain enhancers.** To find sequence motifs that were associated with forebrain expression, we used a discrete, enumerative motif-finding approach<sup>27</sup>. We identified motifs enriched in the training set of forebrain enhancers relative to three sets of background sequences: (1) random sequences from chromosome 16 (ATTAA and GATTA, which we note are motifs present in previously characterized embryonic forebrain enhancers<sup>28,29</sup>), (2) a chromosome 16 set of human–*Fugu* conserved elements (TTNNAAA, CANNNGC and TANNTGA), and (3) a chromosome 16 set of human–*Fugu* sequences that displayed enhancer activity (TTNNITT) (see Supplementary Methods for details). We then combined information from all the motifs for the prediction of new forebrain enhancers in the genome by scoring each of 3,124 human/mouse/*Fugu* non-coding alignments<sup>18</sup> for the number of conserved (found aligned in human/mouse/*Fugu*) matches to each of the 6 significant 5-mers (see Supplementary Methods for details of scoring procedure). The top 30 fragments are available in Supplementary Table 3.

Received 14 June; accepted 22 September 2006.

Published online 5 November 2006.

|                                 | Coordinates (genes)  | Pattern | Positive |
|---------------------------------|--|---------|----------|
| <b>a</b><br>Training set        | Chr. 16: 77068109–77069445<br>( <i>WVVOX</i> , intragenic) |         | 7/10     |
|                                 | Chr. 16: 70812067–70813326<br>( <i>PMFBP1-ATBF1</i> )      |         | 6/7      |
|                                 | Chr. 16: 53208099–53209383<br>( <i>IRX3-IRX5</i> )         |         | 5/5      |
|                                 | Chr. 16: 50228682–50229540<br>( <i>SALL1-CHD9</i> )        |         | 4/6      |
| <b>b</b><br>Predicted enhancers | Chr. 1: 87533642–87535103<br>( <i>LMO4-PKN2</i> )          |         | 9/12     |
|                                 | Chr. 3: 71373108–71375274<br>( <i>FOXP1</i> , intragenic)  |         | 8/9      |
|                                 | Chr. 3: 182256341–182258504<br>( <i>TIM14-SOX2</i> )       |         | 6/8      |
|                                 | Chr. X: 24675039–24677929<br>( <i>POLA</i> , intragenic)   |         | 5/6      |

**Figure 4 | Application of a forebrain enhancer training set to identify forebrain-specific enhancer sequences elsewhere in the human genome.** **a**, The four human–*Fugu* chromosome 16 forebrain enhancers used in the training set. **b**, The four positive forebrain enhancers from the 23 human–*Fugu* genome-wide elements predicted to direct forebrain expression based on the training set in **a**. The UCSC human genome coordinates of the tested fragments (May 2004) and the flanking gene(s) are provided, as well as three representative embryos. Numbers indicate the ratio of forebrain-positive to the total number of stained embryos.

1. Bejerano, G. *et al.* Ultraconserved elements in the human genome. *Science* **304**, 1321–1325 (2004).
2. Roeder, R. G. & Rutter, W. J. Multiple forms of DNA-dependent RNA polymerase in eukaryotic organisms. *Nature* **224**, 234–237 (1969).
3. Goldberg, M. L. *Sequence Analysis of Drosophila Histone Genes*. Ph.D. thesis, Stanford Univ. (1979).
4. Stathopoulos, A. & Levine, M. Genomic regulatory networks and animal development. *Dev. Cell* **9**, 449–462 (2005).
5. Levine, M. & Tjian, R. Transcription regulation and animal diversity. *Nature* **424**, 147–151 (2003).
6. Emission, E. S. *et al.* A common sex-dependent mutation in a RET enhancer underlies Hirschsprung disease risk. *Nature* **434**, 857–863 (2005).
7. Kleinjan, D. A. & van Heyningen, V. Long-range control of gene expression: emerging mechanisms and disruption in disease. *Am. J. Hum. Genet.* **76**, 8–32 (2005).
8. Lettice, L. A. *et al.* A long-range *Shh* enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly. *Hum. Mol. Genet.* **12**, 1725–1735 (2003).
9. Boffelli, D. *et al.* Phylogenetic shadowing of primate sequences to find functional regions of the human genome. *Science* **299**, 1391–1394 (2003).
10. Nobrega, M. A., Ovcharenko, I., Afzal, V. & Rubin, E. M. Scanning human gene deserts for long-range enhancers. *Science* **302**, 413 (2003).
11. Prabhakar, S. *et al.* Close sequence comparisons are sufficient to identify human cis-regulatory elements. *Genome Res.* **16** (7), 855–863 (2006).
12. Woolfe, A. *et al.* Highly conserved non-coding sequences are associated with vertebrate development. *PLoS Biol.* **3**, e7 (2005).
13. Kothary, R. *et al.* Inducible expression of an *hsp68-lacZ* hybrid gene in transgenic mice. *Development* **105**, 707–714 (1989).

14. Rojas, A. *et al.* Gata4 expression in lateral mesoderm is downstream of BMP4 and is activated directly by Forkhead and GATA transcription factors through a distal enhancer element. *Development* **132**, 3405–3417 (2005).
15. Rossant, J., Zirngibl, R., Cado, D., Shago, M. & Giguere, V. Expression of a retinoic acid response element-hsplacZ transgene defines specific domains of transcriptional activity during mouse embryogenesis. *Genes Dev.* **5**, 1333–1344 (1991).
16. Yamagishi, H. *et al.* Tbx1 is regulated by tissue-specific forkhead proteins through a common Sonic hedgehog-responsive enhancer. *Genes Dev.* **17**, 269–281 (2003).
17. Boffelli, D., Nobrega, M. A. & Rubin, E. M. Comparative genomics at the vertebrate extremes. *Nature Rev. Genet.* **5**, 456–465 (2004).
18. Ahituv, N., Prabhakar, S., Poulin, F., Rubin, E. M. & Couronne, O. Mapping cis-regulatory domains in the human genome using multi-species conservation of synteny. *Hum. Mol. Genet.* **14**, 3057–3063 (2005).
19. Kohlhase, J., Wischermann, A., Reichenbach, H., Froster, U. & Engel, W. Mutations in the SALL1 putative transcription factor gene cause Townes-Brocks syndrome. *Nature Genet.* **18**, 81–83 (1998).
20. Buck, A., Kispert, A. & Kohlhase, J. Embryonic expression of the murine homologue of SALL1, the gene mutated in Townes–Brocks syndrome. *Mech. Dev.* **104**, 143–146 (2001).
21. Carroll, S. B. Evolution at two levels: on genes and form. *PLoS Biol.* **3**, e245 (2005).
22. Davidson, E. H. *Genomic Regulatory Systems: In Development and Evolution* (Academic, San Diego, 2001).
23. Lee, T. I. *et al.* Control of developmental regulators by Polycomb in human embryonic stem cells. *Cell* **125**, 301–313 (2006).
24. Bard, J. L. *et al.* An internet-accessible database of mouse developmental anatomy based on a systematic nomenclature. *Mech. Dev.* **74**, 111–120 (1998).
25. Gray, P. A. *et al.* Mouse brain organization revealed through direct genome-scale TF expression analysis. *Science* **306**, 2255–2257 (2004).
26. Poulin, F. *et al.* *In vivo* characterization of a vertebrate ultraconserved enhancer. *Genomics* **85**, 774–781 (2005).
27. van Helden, J., Andre, B. & Collado-Vides, J. Extracting regulatory sites from the upstream region of yeast genes by computational analysis of oligonucleotide frequencies. *J. Mol. Biol.* **281**, 827–842 (1998).
28. Kurokawa, D. *et al.* Regulation of Otx2 expression and its functions in mouse forebrain and midbrain. *Development* **131**, 3319–3331 (2004).
29. Zhou, J., Zwicker, J., Szymanski, P., Levine, M. & Tjian, R. TAFII mutations disrupt Dorsal activation in the *Drosophila* embryo. *Proc. Natl Acad. Sci. USA* **95**, 13483–13488 (1998).

**Supplementary Information** is linked to the online version of the paper at [www.nature.com/nature](http://www.nature.com/nature).

**Acknowledgements** Research was conducted at the E. O. Lawrence Berkeley National Laboratory, under the Programs for Genomic Application, funded by the National Heart, Lung, and Blood Institute, USA as well as the National Human Genome Research Institute, USA, and performed under a Department of Energy Contract with the University of California.

**Author Information** Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints). The authors declare no competing financial interests. Correspondence and requests for materials should be addressed to L.A.P. (LAPennacchio@lbl.gov).